Tigecycline for the Treatment of Acinetobacter Infections: A Case Series
作者： Jason C Gallagher , Heather M Rouse
DOI: 10.1345/APH.1L171
关键词:
摘要: BackgroundAcinetobacter infections resistant to multiple classes of antibiotics have become prevalent in many institutions. Tigecycline has vitro activity against Acinetobacter spp. and been suggested as a therapeutic option these infections.ObjectiveTo describe the clinical microbiologic outcomes patients who received tigecycline for treatment caused by at our institution.MethodsA retrospective review was conducted medical records 29 sequential infections. The assessed efficacy were improvement or cure evaluable patients.Results:Patients median 30 days into hospitalization 11 days. Common indications pneumonia (15 pts.), bacteremia (6), urinary tract infection (3). Positive (clinical improvement) seen 8 (28%) patients. Of 25 microbiologi...
sagepub.com
theannals.com参考文章(19)
M. J. Pickett, M. M. Pedersen, Nonfermentative bacilli associated with man. II. Detection and identification. American Journal of Clinical Pathology. ,vol. 54, pp. 164- 177 ,(1970) , 10.1093/AJCP/54.2.164
Anthony M Nicasio, Joseph L Kuti, David P Nicolau, The Current State of Multidrug-Resistant Gram-Negative Bacilli in North America Pharmacotherapy. ,vol. 28, pp. 235- 249 ,(2008) , 10.1592/PHCO.28.2.235
J Tankovic, P Legrand, G De Gatines, V Chemineau, C Brun-Buisson, J Duval, Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. Journal of Clinical Microbiology. ,vol. 32, pp. 2677- 2681 ,(1994) , 10.1128/JCM.32.11.2677-2681.1994
Byungse Suh, Tatyana Shapiro, Robert Jones, Vilas Satishchandran, Allan L. Truant, In vitro activity of β-lactamase inhibitors against clinical isolates of Acinetobacter species Diagnostic Microbiology and Infectious Disease. ,vol. 21, pp. 111- 114 ,(1995) , 10.1016/0732-8893(95)00020-B
M. E. Jimenez-Mejias, J. Pachon, B. Becerril, J. Palomino-Nicas, A. Rodriguez-Cobacho, M. Revuelta, Treatment of Multidrug-Resistant Acinetobacter baumannii Meningitis with Ampicillin/Sulbactam Clinical Infectious Diseases. ,vol. 24, pp. 932- 935 ,(1997) , 10.1093/CLINIDS/24.5.932
Warren E Rose, Michael J Rybak, Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. ,vol. 26, pp. 1099- 1110 ,(2006) , 10.1592/PHCO.26.8.1099
K. B. Anthony, N. O. Fishman, D. R. Linkin, L. B. Gasink, P. H. Edelstein, E. Lautenbach, Clinical and Microbiological Outcomes of Serious Infections with Multidrug-Resistant Gram-Negative Organisms Treated with Tigecycline Clinical Infectious Diseases. ,vol. 46, pp. 567- 570 ,(2008) , 10.1086/526775
Gail E Reid, Shellee A Grim, Christine A Aldeza, William M Janda, Nina M Clark, Rapid Development of Acinetobacter baumannii Resistance to Tigecycline Pharmacotherapy. ,vol. 27, pp. 1198- 1201 ,(2007) , 10.1592/PHCO.27.8.1198
EJ Ellis Grosse, T Babinchak, N Dartois, G Rose, Ef Loh, Tigecycline 300 and 305 cSSSI Study Groups, None, The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin-Structure Infections: Results of 2 Double-Blind Phase 3 Comparison Studies with Vancomycin-Aztreonam Clinical Infectious Diseases. ,vol. 41, pp. 341- 353 ,(2005) , 10.1086/431675
Federico Perez, Andrea M. Hujer, Kristine M. Hujer, Brooke K. Decker, Philip N. Rather, Robert A. Bonomo, Global Challenge of Multidrug-Resistant Acinetobacter baumannii Antimicrobial Agents and Chemotherapy. ,vol. 51, pp. 3471- 3484 ,(2007) , 10.1128/AAC.01464-06